Pegloticase

Grey

Brand Name(s):Krystexxa

Indication:Severe chronic (long-term) tophaceous gout

Rationale:1

Considered:Mar-13

Review Date:Apr-20

Comments:
NICE TA291
Pegloticase is not recommended within its marketing authorisation, that is, for
treating severe debilitating chronic tophaceous gout in adults who may also
have erosive joint involvement and in whom xanthine oxidase inhibitors at the
maximum medically appropriate dose have failed to normalise serum uric acid,
or for whom these medicines are contraindicated.
People currently receiving pegloticase that is not recommended according to
1.1 should be able to continue treatment until they and their clinician consider it
appropriate to stop. Further information at:
http://www.nice.org.uk/nicemedia/live/14196/64258/64258.pdf
Issued: June 2013